Laboratorios Farmaceuticos Rovi(GB:0ILL)
€69.60+0.25 (+0.36%)
GB:0ILL
Laboratorios Farmaceuticos Rovi financials statements
€69.60
At close:+0.25 (+0.36%)
Laboratorios Farmaceuticos Rovi (0ILL) Ratios
0 Followers
Laboratorios Farmaceuticos Rovi Ratios
GB:0ILL's free cash flow for Q3 2026 was €-2.22M. For the 2026 fiscal year, GB:0ILL's free cash flow was decreased by €-19.00M and operating cash flow was €16.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.14 | 3.14 | 2.55 | 2.12 | 2.66 |
| Quick Ratio | 1.55 | 1.03 | 0.86 | 1.06 | 1.37 |
| Cash Ratio | 0.54 | 0.17 | 0.13 | 0.43 | 0.52 |
| Solvency Ratio | 0.62 | 0.66 | 0.76 | 0.62 | 0.67 |
| Operating Cash Flow Ratio | 1.02 | 0.88 | 0.57 | 0.81 | 0.78 |
| Short-Term Operating Cash Flow Coverage | 8.36 | 7.75 | 14.05 | 28.84 | 50.50 |
| Net Current Asset Value | € 292.87M | € 241.09M | € 252.94M | € 265.75M | € 244.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.14 | 0.08 | 0.08 | 0.10 |
| Debt-to-Equity Ratio | 0.18 | 0.20 | 0.12 | 0.14 | 0.16 |
| Debt-to-Capital Ratio | 0.15 | 0.17 | 0.11 | 0.12 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.11 | 0.12 | 0.07 | 0.08 | 0.10 |
| Financial Leverage Ratio | 1.44 | 1.45 | 1.48 | 1.69 | 1.56 |
| Debt Service Coverage Ratio | 6.42 | 8.26 | 21.74 | 24.56 | 45.33 |
| Interest Coverage Ratio | 60.84 | 76.40 | 234.06 | 301.35 | 200.63 |
| Debt to Market Cap | 0.03 | 0.03 | 0.01 | 0.03 | 0.01 |
| Interest Debt Per Share | 2.44 | 2.28 | 1.28 | 1.37 | 1.34 |
| Net Debt to EBITDA | 0.12 | 0.42 | 0.16 | -0.19 | -0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 60.75% | 62.63% | 58.27% | 63.55% | 59.32% |
| EBIT Margin | 23.29% | 23.53% | 26.69% | 31.62% | 28.26% |
| EBITDA Margin | 27.37% | 27.19% | 29.63% | 34.42% | 31.56% |
| Operating Profit Margin | 23.29% | 23.51% | 26.55% | 31.29% | 27.99% |
| Pretax Profit Margin | 24.65% | 23.27% | 26.57% | 31.55% | 28.15% |
| Net Profit Margin | 18.89% | 17.92% | 20.53% | 24.42% | 23.60% |
| Continuous Operations Profit Margin | 18.88% | 17.94% | 20.53% | 24.42% | 23.57% |
| Net Income Per EBT | 76.63% | 77.03% | 77.28% | 77.40% | 83.82% |
| EBT Per EBIT | 105.84% | 98.97% | 100.07% | 100.83% | 100.58% |
| Return on Assets (ROA) | 14.70% | 16.45% | 21.29% | 22.72% | 20.89% |
| Return on Equity (ROE) | 21.14% | 23.93% | 31.58% | 38.40% | 32.50% |
| Return on Capital Employed (ROCE) | 22.36% | 26.58% | 36.71% | 43.75% | 33.48% |
| Return on Invested Capital (ROIC) | 16.52% | 19.73% | 27.75% | 33.14% | 27.74% |
| Return on Tangible Assets | 15.27% | 17.15% | 22.24% | 23.69% | 22.05% |
| Earnings Yield | 4.32% | 4.24% | 5.46% | 10.36% | 3.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.19 | 5.90 | 5.79 | 4.44 | 4.05 |
| Payables Turnover | 4.28 | 3.29 | 3.22 | 2.41 | 2.71 |
| Inventory Turnover | 1.01 | 0.86 | 1.02 | 0.96 | 1.07 |
| Fixed Asset Turnover | 2.25 | 2.66 | 3.27 | 3.79 | 3.57 |
| Asset Turnover | 0.78 | 0.92 | 1.04 | 0.93 | 0.89 |
| Working Capital Turnover Ratio | 2.06 | 2.37 | 2.60 | 2.53 | 2.33 |
| Cash Conversion Cycle | 362.01 | 372.79 | 305.97 | 312.46 | 294.89 |
| Days of Sales Outstanding | 87.17 | 61.89 | 63.06 | 82.20 | 90.06 |
| Days of Inventory Outstanding | 360.18 | 421.98 | 356.36 | 381.97 | 339.57 |
| Days of Payables Outstanding | 85.34 | 111.07 | 113.45 | 151.71 | 134.75 |
| Operating Cycle | 447.35 | 483.87 | 419.42 | 464.17 | 429.64 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.62 | 2.70 | 2.19 | 4.44 | 2.70 |
| Free Cash Flow Per Share | 2.35 | 1.48 | 1.12 | 3.48 | 1.96 |
| Dividend Paid and CapEx Coverage Ratio | 1.64 | 1.17 | 0.91 | 2.32 | 2.41 |
| Capital Expenditure Coverage Ratio | 2.84 | 2.22 | 2.05 | 4.62 | 3.65 |
| Operating Cash Flow Coverage Ratio | 1.52 | 1.21 | 1.73 | 3.29 | 2.04 |
| Operating Cash Flow to Sales Ratio | 0.25 | 0.18 | 0.14 | 0.29 | 0.23 |
| Free Cash Flow Yield | 3.70% | 2.36% | 1.86% | 9.66% | 2.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 23.09 | 23.58 | 18.31 | 9.66 | 26.71 |
| Price-to-Sales (P/S) Ratio | 4.37 | 4.23 | 3.76 | 2.36 | 6.30 |
| Price-to-Book (P/B) Ratio | 4.89 | 5.64 | 5.78 | 3.71 | 8.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 27.03 | 42.43 | 53.73 | 10.35 | 37.68 |
| Price-to-Operating Cash Flow Ratio | 17.52 | 23.34 | 27.55 | 8.11 | 27.36 |
| Price-to-Earnings Growth (PEG) Ratio | 7.71 | -1.25 | -1.55 | 0.27 | 0.18 |
| Enterprise Value Multiple | 16.07 | 15.96 | 12.85 | 6.66 | 19.85 |
| Enterprise Value | 3.27B | 3.31B | 3.16B | 1.88B | 4.06B |
| EV to EBITDA | 16.07 | 15.96 | 12.85 | 6.66 | 19.85 |
| EV to Sales | 4.40 | 4.34 | 3.81 | 2.29 | 6.26 |
| EV to Free Cash Flow | 27.23 | 43.58 | 54.42 | 10.07 | 37.45 |
| EV to Operating Cash Flow | 17.65 | 23.97 | 27.90 | 7.89 | 27.19 |
| Tangible Book Value Per Share | 12.57 | 10.68 | 9.83 | 9.08 | 7.80 |
| Shareholders’ Equity Per Share | 12.99 | 11.16 | 10.41 | 9.73 | 8.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.23 | 0.23 | 0.23 | 0.16 |
| Revenue Per Share | 14.54 | 14.90 | 16.01 | 15.29 | 11.71 |
| Net Income Per Share | 2.75 | 2.67 | 3.29 | 3.73 | 2.76 |
| Tax Burden | 0.77 | 0.77 | 0.77 | 0.77 | 0.84 |
| Interest Burden | 1.06 | 0.99 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.05 | 0.03 | 0.00 | 0.03 | 0.04 |
| SG&A to Revenue | 0.31 | 0.05 | 0.15 | 0.02 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.32 | 0.78 | 0.51 | 0.92 | 0.82 |
Currency in EUR

